Results 1 to 10 of about 55,676 (335)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases [PDF]

Frontiers in Immunology, 2022
The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon
doaj   +2 more sources

Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes [PDF]

Biomedicines, 2021
Crosstalk between synovial fibroblasts (SF) and immune cells plays a central role in the development of rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi) have proven efficacy in the treatment of RA, although clinical responses are heterogeneous ...
Nina Yao, Theresa Tretter, Peter Kvacskay, Wolfgang Merkt, Norbert Blank, Hanns-Martin Lorenz, Lars-Oliver Tykocinski   +6 more
doaj   +2 more sources

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones [PDF]

Molecules, 2023
Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses.
Kamonpan Sanachai, Panupong Mahalapbutr, Lueacha Tabtimmai, Supaphorn Seetaha, Nantawat Kaekratoke, Supakarn Chamni, Syed Sikander Azam, Kiattawee Choowongkomon, Thanyada Rungrotmongkol   +8 more
doaj   +2 more sources

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases [PDF]

Pharmaceuticals, 2019
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK).
Annie Mayence, Jean Jacques Vanden Eynde   +1 more
doaj   +2 more sources

Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis [PDF]

Frontiers in Medicine, 2022
BackgroundJAK (Janus kinases) inhibitors have been proposed as a promising treatment option for the coronavirus disease-2019 (COVID-19). However, the benefits of JAK inhibitors and the optimum thereof for COVID-19 have not been adequately defined ...
Jianyi Niu, Jianyi Niu, Zhiwei Lin, Zhiwei Lin, Zhenfeng He, Zhenfeng He, Xiaojing Yang, Xiaojing Yang, Lijie Qin, Lijie Qin, Shengchuan Feng, Shengchuan Feng, Lili Guan, Lili Guan, Luqian Zhou, Luqian Zhou, Rongchang Chen, Rongchang Chen, Rongchang Chen   +18 more
doaj   +2 more sources

Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases [PDF]

Molecules, 2018
Aberrant activations of the STAT3 (signal transducer and activator of transcription 3) signaling pathway are associated with cancer and inflammatory diseases.
Man Liu, Chengqian Xiao, Mingwei Sun, Minjia Tan, Lihong Hu, Qiang Yu   +5 more
doaj   +2 more sources

Pharmacological inhibition of the Janus Kinases enhances ASCL1 protein stability and transcriptional activity. [PDF]

Mol Biol Rep
Hanspal MA, Presland J, Shkura K, Veiga MK, Gillotin S.   +4 more
europepmc   +3 more sources

Janus kinase inhibitors - their current applications and future prospects [PDF]

Farmacja Polska, 2022
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska, Karolina Żurawska, Maciej Arciszewski, Arnold Kukowka, Bolesław Banach   +4 more
doaj   +1 more source

Identification of the protein kinases Pyk3 and Phg2 as regulators of the STATc-mediated response to hyperosmolarity [PDF]

, 2014
Cellular adaptation to changes in environmental osmolarity is crucial for cell survival. In Dictyostelium, STATc is a key regulator of the transcriptional response to hyperosmotic stress. Its phosphorylation and consequent activation is controlled by two
A Kortholt, A Kortholt, AA Noegel, Adrian John Harwood, BK Gilsbach, C Blanc, Christoph S. Clemen, CR Thompson, DE Levy, H Kiu, H Kuwayama, H Towbin, J Faix, J Langenick, J Na, Jeffrey G. Williams, Jianbo Na, JM Goldberg, K Adler, KL Williams, L Gebbie, Linh Hai Vu, Ludwig Eichinger, M Brink, M Fukuzawa, M Gamper, MR Lee, NS Lee, P Farbrother, P Gatsios, R Kang, RH Insall, T Araki, T Araki, T Araki, T Araki, Tsuyoshi Araki, UK Laemmli   +37 more
core   +19 more sources

Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases [PDF]

ACS Omega, 2020
Kamonpan Sanachai, Panupong Mahalapbutr, Kiattawee Choowongkomon, Rungtiva P. Poo-arporn, Peter Wolschann, Thanyada Rungrotmongkol   +5 more
doaj   +2 more sources